Darvulumab is an immune checkpoint inhibitor that targets the PD-L1 protein on cancer cells, helping the immune system to identify and attack the cancer cells.
Efficacy was established on the basis of findings in the DUO-E trial, which included patients with primary advanced or recurrent endometrial cancer.
Efficacy was established on the basis of findings in the DUO-E trial, which included patients with primary advanced or recurrent endometrial cancer.
Therapeutics, Diagnostics, and Deep Learning Models
Darvulumab is an immune checkpoint inhibitor that targets the PD-L1 protein on cancer cells, helping the immune system to identify and attack the cancer cells.
Efficacy was established on the basis of findings in the DUO-E trial, which included patients with primary advanced or recurrent endometrial cancer.
Efficacy was established on the basis of findings in the DUO-E trial, which included patients with primary advanced or recurrent endometrial cancer.
Therapeutics, Diagnostics, and Deep Learning Models
Darvulumab is an immune checkpoint inhibitor that targets the PD-L1 protein on cancer cells, helping the immune system to identify and attack the cancer cells.
Efficacy was established on the basis of findings in the DUO-E trial, which included patients with primary advanced or recurrent endometrial cancer.
Efficacy was established on the basis of findings in the DUO-E trial, which included patients with primary advanced or recurrent endometrial cancer.
Therapeutics, Diagnostics, and Deep Learning Models